Signe Caksa
Overview
Explore the profile of Signe Caksa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
210
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saunders R, Kilroe K, Joseph T, Caksa S, Bouxsein M, Misra M, et al.
JBMR Plus
. 2023 Nov;
7(11):e10813.
PMID: 38025039
Type 1 diabetes (T1D) confers an increased risk of fracture and is associated with lower bone mineral density (BMD) and altered microarchitecture compared with controls. Adequate calcium (Ca) intake promotes...
2.
Rosenbaum S, Caksa S, Stefanski C, Trachtenberg I, Wilson H, Wilski N, et al.
Mol Cancer Res
. 2023 Oct;
22(2):209-220.
PMID: 37847239
Implications: These data support a role for SOX10 expression altering the response to T cell-mediated cell death and contribute to a broader understanding of the interaction between immune cells and...
3.
Purwin T, Caksa S, Sacan A, Capparelli C, Aplin A
iScience
. 2023 Aug;
26(9):107472.
PMID: 37636077
Evidence is mounting for cross-resistance between immune checkpoint and targeted kinase inhibitor therapies in cutaneous melanoma patients. Since the loss of the transcription factor, SOX10, causes tolerance to MAPK pathway...
4.
Glasheen M, Caksa S, Young A, Wilski N, Ott C, Chervoneva I, et al.
Mol Cancer Ther
. 2023 Jun;
22(9):1087-1099.
PMID: 37343247
Drug tolerance and minimal residual disease (MRD) are likely to prelude acquired resistance to targeted therapy. Mechanisms that allow persister cells to survive in the presence of targeted therapy are...
5.
Gehman S, Ackerman K, Caksa S, Rudolph S, Hughes J, Garrahan M, et al.
Int J Sport Nutr Exerc Metab
. 2022 May;
32(5):325-333.
PMID: 35523419
Bone stress injuries (BSIs) are common among athletes and have high rates of recurrence. However, risk factors for multiple or recurrent BSIs remain understudied. Thus, we aimed to explore whether...
6.
Caksa S, Baqai U, Aplin A
Pharmacol Ther
. 2022 May;
239:108200.
PMID: 35513054
Melanoma is a cancer of the pigment-producing cells of the body and its incidence is rising. Targeted inhibitors that act against kinases in the MAPK pathway are approved for BRAF-mutant...
7.
Capparelli C, Purwin T, Glasheen M, Caksa S, Tiago M, Wilski N, et al.
Nat Commun
. 2022 Mar;
13(1):1381.
PMID: 35296667
Cellular plasticity contributes to intra-tumoral heterogeneity and phenotype switching, which enable adaptation to metastatic microenvironments and resistance to therapies. Mechanisms underlying tumor cell plasticity remain poorly understood. SOX10, a neural...
8.
9.
Rappaport J, Entezari A, Caspi A, Caksa S, Jhaveri A, Stanek T, et al.
Cell Mol Gastroenterol Hepatol
. 2021 Dec;
13(4):1276-1296.
PMID: 34954189
Background & Aims: Sporadic colorectal cancers arise from initiating mutations in APC, producing oncogenic β-catenin/TCF-dependent transcriptional reprogramming. Similarly, the tumor suppressor axis regulated by the intestinal epithelial receptor GUCY2C is...
10.
Rosenbaum S, Tiago M, Caksa S, Capparelli C, Purwin T, Kumar G, et al.
Cell Rep
. 2021 Dec;
37(10):110085.
PMID: 34879275
Developmental factors may regulate the expression of immune modulatory proteins in cancer, linking embryonic development and cancer cell immune evasion. This is particularly relevant in melanoma because immune checkpoint inhibitors...